pembrolizumab
merck
['sclc', 'lcsm,(-blcsm)', 'nsclc', 'pembro']
adjuvant pembrolizumab demonstrates dfs benefit in key subgroups of resected early-stage nsclc #asco22 #lcsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.